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ABSTRACT 
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for the design, conduct, 
performance, monitoring, auditing, recording, analyses and reporting of clinical trials. It also serves to protect the rights, 
integrity and confidentiality of trial subjects. It is very important to understand the background of the formation of the 
ICH-GCP guidelines as this, in itself, explains the reasons and the need for doing so. In this paper, we address the 
historical background and the events that led up to the formation of these guidelines. Today, the ICH-GCP guidelines are 
used  in  clinical  trials  throughout  the  globe  with  the  main  aim  of  protecting  and  preserving  human  rights.  © 2008 
Biomedical Imaging and Intervention Journal. All rights reserved. 
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DEFINITION 
Good  Clinical  Practice  (GCP)  is  an  international 
ethical  and  scientific  quality  standard  for  the  design, 
conduct,  performance,  monitoring,  auditing,  recording, 
analyses and reporting of clinical trials. GCP provides 
assurance that the data and reported results are credible 
and  accurate,  and  that  the  rights,  integrity  and 
confidentiality  of  trial  subjects  are  respected  and 
protected  [1].  It  was  finalised  in  1996  and  became 
effective in 1997, but was not enforced by law at that 
time.  The  Medicines  for  Human  Use  (Clinical  Trials) 
Regulations  2004  and  the  European  Union  (EU) 
Directive on Good Clinical Practice changed the world 
perspective , and compliance with GCP is now a legal 
obligation in the UK/Europe for all trials involving the 
investigation of medicinal products [2]. 
HISTORICAL BACKGROUND 
It is very important to understand the background of 
the formation of the ICH-GCP guidelines as this, in itself, 
explains the reasons and the need for doing so (Table 1). 
The concept of the ‘good physician‘ dates back to the 
ancient  world  and  it  is  evidenced  by  the  Hippocratic 
Oath (460 BC). In the United States, the first landmark in 
the regulation of drugs was the Food and Drugs Act of 
1906. This was a result of harmful and lethal drugs that 
could be bought across the counter just like any other 
consumer  product.  Some  examples  are  ‘Grandma’s 
Secret’  and  ‘Kopp’s  Baby’s  Friend’  which  contained 
large  doses  of  morphine,  as  well  as  ‘Dr  King’s 
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Consumption Cure‘ and ‘Dr Bull’s Cough Syrup‘ which 
contained  morphine  and  chloroform  [3].  In  1938,  the 
Federal Food, Drug and Cosmetic Act was enacted by 
the  Food  and  Drug  Administration  (FDA)  and  for  the 
first time, manufacturers were required to test drugs for 
safety and present the evidence of safety testing to the 
FDA prior to marketing [3].  
In 1947, the Nuremberg Code was created as a result 
of  the  unethical  and  horrific  experiments  carried  out 
during  World  War  II  at  Nazi  war  camps  by  German 
physicians, who were subsequently tried and charged at 
the  Nuremberg  Military  Tribunal.  This  code  states  the 
need for a scientific basis in research on human subjects 
and voluntary consent and protection of participants [4,5]. 
The Universal Declaration of Human Rights (December 
10th  1948)  was  also  adopted  and  proclaimed  by  the 
United Nations after the atrocities of World War II and it 
further reiterated the human factor involved in medical 
experiments.  
In 1964, the Declaration of Helsinki was developed 
by the World Medical Association, forming the basis for 
the  ethical  principles  that  underlie  the  ICH-GCP 
guidelines we have today. The focus of this declaration is 
the protection of the rights of human subjects and this is 
clear in its introduction [6]: 
“The World Medical Association has developed 
the Declaration of Helsinki  as a statement of 
ethical  principles  to  provide  guidance  to 
physicians  and  other  participants  in  medical 
research  involving  human  subjects.  It  is  the 
duty of the physician to promote and safeguard 
the  health  of  the  people.  The  physician’s 
knowledge and conscience are dedicated to the 
fulfilment of this duty”   
In 1962 the world was once again shocked by the 
severe  foetal  limb  deformities  linked  to  the  use  of 
maternal thalidomide. In fact this drug reaction was only 
discovered  after  10,000  infants  were  born  in  over  20 
countries worldwide. In response to this, the Kefauver-
Harris  Amendments  were  passed  which  required  the 
FDA to evaluate all new drugs for safety and efficacy [3].  
Another important milestone in the formation of the 
ICH-GCP  guidelines  was  The  Belmont  Report  which 
was issued in April 1979 by the National Commission 
for  Protection  of  Human  Subjects  of  Biomedical  and 
Behavioural Research [7]. The principles of this report 
are as follows: 
1.  Respect  for  Persons:  This  principle 
acknowledges the dignity and freedom of every 
person. It requires obtaining informed consent 
from  research  subjects  (or  their  legally 
authorised representatives) 
2.  Beneficence:  This  principle  requires  that 
researchers  maximise  benefits  and  minimise 
harms  associated  with  research.  Research-
related risks must be reasonable in light of the 
expected benefits. 
3.  Justice:  This  principle  requires  equitable 
selection and recruitment and fair treatment of 
research subjects. 
In 1982, the World Health Organization (WHO) and 
the Council for International Organizations of Medical 
Sciences  (CIOMS)  issued  a  document  entitled 
‘International  Guidelines  for  Biomedical  Research 
Involving Human Subjects‘. This document was released 
to help developing countries apply the principles of the 
Declaration  of  Helsinki  and  the  Nuremberg  Code  [3]. 
Worldwide, many organisations and committees issued 
various documents and guidelines on the same issue, and 
a decision was taken to consolidate all these guidelines 
into one universal guideline to be used globally. 
In  an  effort  to  overcome  international  GCP 
inconsistencies  throughout  the  countries,  the 
International Conference for Harmonisation of Technical 
Requirements  for  Registration  of  Pharmaceuticals  for 
Human Use (ICH) issued the ICH Guidelines: Topic E6 
Guideline for GCP. This guideline was approved on 17 
July  1996  and  implemented  for  clinical  trials  from  17 
January 1997. The participants of these guidelines were 
representatives  of  authorities  and  pharmaceutical 
Table 1  Historical background of GCP 
460BC  Oath of Hippocrates 
1930’s  U.S. Food, Drugs and Cosmetic Act 
1947  Nuremberg Code 
Dec. 10th 1948  Declaration of Human Rights 
1962  Kefauver-Harris Amendment 
1964, revised 2000  Declaration of Helsinki 
1979  The Belmont Report 
1982  International Guidelines for Biomedical Research Involving Human Subjects 
1996  ICH-GCP guidelines issued 
1997  ICH-GCP guidelines becomes law in some countries 
 A Vijayananthan et al. Biomed Imaging Interv J 2008; 4(1):e5    3 
    This page number is not 
    for citation purposes 
companies from the EU, Japan and the United States as 
well as those of Australia, Canada, the Nordic countries 
and WHO [8]. 
ICH-GCP 
The ICH-GCP is a harmonised standard that protects 
the  rights,  safety  and  welfare  of  human  subjects, 
minimises  human exposure to investigational products, 
improves quality of data, speeds up  marketing of  new 
drugs  and  decreases  the  cost  to  sponsors  and  to  the 
public.  Compliance  with  this  standard  provides  public 
assurance that the rights, safety and well-being of trial 
subjects are protected and consistent with the principles 
of the Declaration of Helsinki, and that the clinical trial 
data  is  credible  [8].  A  historical  background  of  the 
reasons  and  the  importance  of  GCP  is  summarised  in 
Table 2. 
There are 13 core principles of ICH-GCP and they 
are as follows: 
  
1.  Clinical  trials  should  be  conducted  in 
accordance  with  ethical  principles  that  have 
their origin in the Declaration of Helsinki, and 
that are consistent with GCP and the applicable 
regulatory requirement(s). 
2.  Before a trial is initiated, foreseeable risks and 
inconveniences  should  be  weighed  against 
anticipated  benefit  for  the  individual  trial 
subject and society. A trial should be initiated 
and  continued  only  if  the  anticipated  benefits 
justify the risks. 
3.  The  rights,  safety  and  well-being  of  the  trial 
subjects are the most important considerations 
and should prevail over interest of science and 
society. 
4.  The  available  non-clinical  and  clinical 
information  on  an  investigational  product 
should  be  adequate  to  support  the  proposed 
clinical trial. 
5.  Clinical  trials  should  be  scientifically  sound, 
and described in clear, detailed protocol. 
6.  A trial should be conducted in compliance with 
the protocol that has received prior institutional 
review  board  (IRB)/  independent  ethics 
committee (IEC) approval/favourable opinion. 
7.  The  medical  care  given  to,  and  medical 
decisions  made  on  behalf  of  subjects  should 
always  be  the  responsibility  of  a  qualified 
physician or, when appropriate, of a qualified 
dentist. 
8.  Each individual involved in conducting a trial 
should be qualified by education, training, and 
experience  to  perform  his  or  her  respective 
task(s). 
9.  Freely  given  informed  consent  should  be 
obtained  from  every  subject  prior  to  clinical 
trial participation. 
10.  All clinical trial information should be recorded, 
handled,  and  stored  in  a  way  that  allows  its 
accurate  reporting,  interpretation  and 
verification. 
11.  The  confidentiality  of  records  that  could 
identify subjects should be protected, respecting 
the  privacy  and  confidentiality  rules  in 
accordance  with  the  applicable  regulatory 
requirement(s). 
12.  Investigational  products  should  be 
manufactured,  handled  and  stored  in 
accordance  with  applicable  Good 
Manufacturing Practice (GMP). They should be 
used in accordance with the approved protocol. 
13.  Systems with procedures that assure the quality 
of  every  aspect  of  the  trial  should  be 
implemented. 
These  principles  are  self-explanatory  and,  when 
summarised, simply mean:  
All clinical trials should be conducted in accordance 
with  ethical  principles,  sound  scientific  evidence  and 
clear detailed protocols. The benefits of conducting trials 
should outweigh the risks. The rights, safety and well-
being of trial participants are of paramount importance 
and  these  should  be  preserved  by  obtaining  informed 
consent and maintaining confidentiality. The care must 
be  given  by  appropriately  qualified  personnel  with 
adequate experience. Records should be easily accessible 
and  retrievable  for  accurate  reporting,  verification  and 
interpretation.  Investigational  products  should  be 
manufactured according to Good Manufacturing Practice 
(8).  
It  is  also  important  to  mention  the  participants  of 
GCP in clinical trials and their respective responsibilities. 
These are summarised in Table 3. 
GCP IN THE ASIA PACIFIC REGION 
Since  the  conception  of  the  ICH-GCP  guidelines, 
many  countries  in  the  Asia-Pacific  region  realised  the 
need to formulate guidelines of their own based on the 
Table 2  Reasons for GCP 
Increased Ethical Awareness 
Improved Trial Methods 
Clinical Trial Concept Better Understood 
Public/Political Concern over Safety Aspects 
Frauds and Accidents during Trials 
Growing Research and Development Costs 
Increasing Competition 
Mutual Recognition of Data 
New Market Structure 
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framework of the original guidelines [7]. This is clearly 
seen in Table 4 that tabulates the adoption of GCP in our 
country and its neighbours. 
In Malaysia, similar guidelines were formulated in 
the  wake  of  greater  demand  by  the  pharmaceutical 
industry  to  conduct  clinical  trials  in  the  country.  The 
Malaysian  Guidelines  for  GCP  was  first  published  in 
October  1999  and  the  second  edition  was  released  in 
January 2004. The guideline adopts the basic principle 
outlined  by  the  International  Committee  on 
Harmonization  of  Good  Clinical  Practice  (ICH-GCP) 
with some modifications to suit local requirements [1,7]. 
CONCLUSION 
The importance of GCP lies in the question ‘why’ 
and ‘how’ GCP trials came about. To know the answer to 
this, we have to look to the historical background that led 
to the formulation of GCP guidelines in the United States 
and Europe and also to the formation of the ICH. The 
events that led up to the culmination of the ICH-GCP 
guidelines brought forth public awareness that there was 
a need to control and regulate clinical trials dealing with 
drugs and human subjects. The violation of human rights 
played a large role and that is why the Declaration of 
Helsinki  and  The  Nuremberg  Code  remain  as  the 
framework  of  the  present  guidelines.  The  ICH-GCP 
guidelines are therefore considered the ‘bible’ of clinical 
trials, and have become a global law which safeguards 
humanity as we know it today. 
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Table 3  GCP participants 
Regulatory Authorities  Review submitted clinical data and conduct inspections  
The sponsor  Company or institution/organization which takes responsibility for 
initiation, management and financing of clinical trial 
The project monitor  Usually appointed by sponsor 
The investigator  Responsible for conduct of clinical trial at the trial site. Team leader. 
The pharmacist at trial location  Responsible for maintenance, storage and dispensing of 
investigational products eg. Drugs in clinical trials 
Patients  Human subjects 
Ethical review board or Committee 
for protection of subjects 
Appointed by Institution or if not available then the Authoritative 
Health Body in that Country will be responsible 
Committee to monitor large trials  Overseas Sponsors eg. Drug Companies 
 
Table 4  GCP Adoption in the Asia Pacific Region 
Original ICH-GCP Guidelines  1996 
Singapore GCP   1998 
Chinese GCP  1999 
Malaysian GCP  1999, revised 2004 
Thailand  2000 
Indonesia  2001 
 